February 11, 2020 / 12:48 PM / 15 days ago

BRIEF-Marker Therapeutics Announces Update To Its Clinical Program In Aml

Feb 11 (Reuters) - Marker Therapeutics Inc:

* MARKER THERAPEUTICS ANNOUNCES UPDATE TO ITS CLINICAL PROGRAM IN AML

* MARKER THERAPEUTICS INC - U.S. FDA LIFTS CLINICAL HOLD ON PHASE 2 ACUTE MYELOID LEUKEMIA (AML) TRIAL

* MARKER - FDA PLACES PARTIAL HOLD ON TRIAL FOR USE OF REAGENT FROM ALTERNATIVE VENDOR UNTIL FINAL DATA AND CERTIFICATE OF ANALYSIS ARE ACCEPTED BY FDA

* MARKER - CURRENTLY ESTIMATES ALTERNATIVE SUPPLIER WILL DELIVER FINAL REAGENT, WITH FINAL DATA & CERTIFICATE OF ANALYSIS REQUIRED BY FDA, BY END OF Q2

* MARKER THERAPEUTICS - DOES NOT CURRENTLY EXPECT PARTIAL CLINICAL HOLD TO SIGNIFICANTLY IMPACT SITE AND PATIENT ENROLLMENT OF AML TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below